Immix Biopharma, Inc. (NASDAQ:IMMX)
IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mice study
IMX-110 response rate surpassed standard of care doxorubicin’s response rate of 0% after 1 cycle of treatment in the same study
IMX-110 is in clinical development for STS, a $3 billion market expected to grow to $6.5 billion by 2030
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.